Rhumbline Advisers Buys 1,824 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Rhumbline Advisers raised its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 2.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 65,163 shares of the company’s stock after purchasing an additional 1,824 shares during the quarter. Rhumbline Advisers owned approximately 0.07% of ARS Pharmaceuticals worth $687,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC increased its position in shares of ARS Pharmaceuticals by 93.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 344,171 shares of the company’s stock valued at $3,631,000 after buying an additional 165,950 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in ARS Pharmaceuticals by 10.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 20,607 shares of the company’s stock valued at $217,000 after acquiring an additional 1,962 shares in the last quarter. Barclays PLC grew its holdings in shares of ARS Pharmaceuticals by 189.7% during the 3rd quarter. Barclays PLC now owns 111,666 shares of the company’s stock worth $1,618,000 after acquiring an additional 73,127 shares during the period. Geode Capital Management LLC grew its holdings in shares of ARS Pharmaceuticals by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,234,805 shares of the company’s stock worth $17,909,000 after acquiring an additional 38,927 shares during the period. Finally, XTX Topco Ltd bought a new position in shares of ARS Pharmaceuticals in the 3rd quarter worth approximately $250,000. 68.16% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. William Blair reaffirmed an “outperform” rating on shares of ARS Pharmaceuticals in a research report on Monday, March 3rd. Raymond James upped their price objective on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a “strong-buy” rating in a report on Tuesday, January 14th. Scotiabank assumed coverage on shares of ARS Pharmaceuticals in a report on Friday. They set a “sector outperform” rating and a $30.00 target price for the company. Leerink Partners upped their price target on ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. Finally, Oppenheimer assumed coverage on ARS Pharmaceuticals in a research report on Monday, February 10th. They set an “outperform” rating and a $40.00 price objective for the company. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, ARS Pharmaceuticals presently has an average rating of “Buy” and an average target price of $29.00.

Insider Buying and Selling at ARS Pharmaceuticals

In related news, insider Justin Chakma sold 27,272 shares of the business’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $12.06, for a total value of $328,900.32. Following the sale, the insider now owns 136,380 shares in the company, valued at approximately $1,644,742.80. The trade was a 16.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Sarina Tanimoto sold 100,000 shares of the business’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $13.16, for a total transaction of $1,316,000.00. Following the completion of the sale, the insider now owns 1,148,499 shares in the company, valued at approximately $15,114,246.84. This trade represents a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 401,872 shares of company stock valued at $4,845,916 in the last 90 days. Insiders own 40.10% of the company’s stock.

ARS Pharmaceuticals Stock Up 0.6 %

NASDAQ:SPRY opened at $10.85 on Friday. The business’s 50-day simple moving average is $11.87 and its two-hundred day simple moving average is $13.16. ARS Pharmaceuticals, Inc. has a 52 week low of $7.55 and a 52 week high of $18.51. The stock has a market cap of $1.05 billion, a PE ratio of -21.27 and a beta of 1.03.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.